Nymox said that compared to baseline, symptoms of urgency to urinate reduced by 52% at 90 days after a single treatment with NX-1207, and the improvement was positive compared to double-blinded placebo control patients.
The study results showed that NX-1207 can better improve the signs and symptoms of BPH better that double-blinded placebo and study controls and is higher than the improvement reported for approved drugs for BPH.
Additionally in the trial, men treated with NX-1207 reported improvement in BPH symptoms 3 months after a single NX-1207 treatment.
In two multi-center Phase 2 US prospective randomised blinded clinical trials, the aggregated mean improvement in the BPH symptom score for 2.5mg NX-1207 was 10.3 points or a 44% improvement in BPH symptom score.